The fate of chemoresistance in triple negative breast cancer (TNBC)

BBA Clinical

Volumn 3, Issue , 2015, Pages 257-275

  O'Reilly, Elma A ^a,b   Gubbins, Luke ^a   Sharma, Shiva ^a,b   Tully, Riona ^a   Guang, Matthew Ho Zhing ^a   Weiner Gorzel, Karolina ^a   McCaffrey, John ^b   Harrison, Michele ^b   Furlong, Fiona ^c   Kell, Malcolm ^b   McCann, Amanda ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Cellular fates; Cellular senescence; Chemoresistance; Hypoxia; Triple negative breast cancer (TNBC)

Indexed keywords

ANTHRACYCLINE; BICALUTAMIDE; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERIBULIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; IXABEPILONE; LAPATINIB; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TEMOZOLOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN; VELIPARIB;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL PROTECTION; CELL VIABILITY; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPHOCYTIC INFILTRATION; MESENCHYMAL STEM CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SURVIVAL; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

EID: 84926046243     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2015.03.003     Document Type: Review

References (238)

1. Schneider B.P., Winer E.P., Foulkes W.D., Garber J., Perou C.M., Richardson A., et al. Triple-negative breast cancer: risk factors to potential targets. Clin. Cancer Res. 2008, 14:8010-8018. 10.1158/1078-0432.CCR-08-1208.
2. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007, 13:2329-2334. 10.1158/1078-0432.CCR-06-1109.
3. Wolff A.C., Hammond M.E.H., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 2013, 31:3997-4013. 10.1200/JCO.2013.50.9984.
4. Jensen E.V., Desombre E.R., Hurst D.J., Kawashima T., Jungblut P.W. Estrogen-receptor interactions in target tissues. Arch. Anat. Microsc. Morphol. Exp. 1967, 56:547-569. (http://www.ncbi.nlm.nih.gov/pubmed/5615176).
5. McGuire W.L. Estrogen receptors in human breast cancer. J. Clin. Invest. 1973, 52:73-77. 10.1172/JCI107175.
6. McCullough A.E., Dell'orto P., Reinholz M.M., Gelber R.D., Dueck A.C., Russo L., et al. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Res. Treat. 2014, 143:485-492. 10.1007/s10549-013-2827-0.
7. Hede K. Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J. Natl. Cancer Inst. 2008, 100(836-7):844. 10.1093/jnci/djn200.
8. Welsh A.W., Moeder C.B., Kumar S., Gershkovich P., Alarid E.T., Harigopal M., et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J. Clin. Oncol. 2011, 29:2978-2984. 10.1200/JCO.2010.32.9706.
9. Hammond M.E.H., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529.
10. Khoshnoud M.R., Löfdahl B., Fohlin H., Fornander T., Stål O., Skoog L., et al. Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Res. Treat. 2011, 126:421-430. 10.1007/s10549-010-1202-7.
11. Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., Schnitt S.J. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J. Clin. Oncol. 1999, 17:1983-1987.
12. Pauletti G., Godolphin W., Press M.F., Slamon D.J. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996, 13:63-72.
13. Press M.F., Bernstein L., Thomas P.A., Meisner L.F., Zhou J.Y., Ma Y., et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 1997, 15:2894-2904.
14. Tubbs R.R., Pettay J.D., Roche P.C., Stoler M.H., Jenkins R.B., Grogan T.M. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J. Clin. Oncol. 2001, 19:2714-2721.
15. Lebeau A., Deimling D., Kaltz C., Sendelhofert A., Iff A., Luthardt B., et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J. Clin. Oncol. 2001, 19:354-363. (http://www.ncbi.nlm.nih.gov/pubmed/11208826).
16. Mass R., Sanders C., Charlene K. The Concordance Between the Clinical Trials Assay (CTA) and Fluorescence in Situ Hybridization (FISH) in the Herceptin Pivotal Trials. Am. Soc. Clin. Oncol. 2000, A291. (http://life.nthu.edu.tw/~b821605/herceptinew/ab291.htm).
17. Rakha E.A., Starczynski J., Lee A.H.S., Ellis I.O. The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice. Histopathology 2014, 64:609-615. 10.1111/his.12357.
18. Viale G., Rotmensz N., Maisonneuve P., Bottiglieri L., Montagna E., Luini A., et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res. Treat. 2009, 116:317-328. 10.1007/s10549-008-0206-z.
19. Haffty B.G., Yang Q., Reiss M., Kearney T., Higgins S.A., Weidhaas J., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol. 2006, 24:5652-5657. 10.1200/JCO.2006.06.5664.
20. Anders C., Carey L.A. Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 2008, 22:1233-1239. (discussion 1239-40, 1243. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2868264&tool=pmcentrez&rendertype=abstract).
21. Anders C.K., Carey L.A. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin. Breast Cancer 2009, 9(Suppl. 2):S73-S81. 10.3816/CBC.2009.s.008.
22. Morris G.J., Naidu S., Topham A.K., Guiles F., Xu Y., McCue P., et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007, 110:876-884. 10.1002/cncr.22836.
23. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502. 10.1001/jama.295.21.2492.
24. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13:4429-4434. 10.1158/1078-0432.CCR-06-3045.
25. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093.
26. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12:R68. 10.1186/bcr2635.
27. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13820-13825. 10.1073/pnas.0905718106.
28. Rakha E.A., Reis-Filho J.S., Ellis I.O. Basal-like breast cancer: a critical review. J. Clin. Oncol. 2008, 26:2568-2581. 10.1200/JCO.2007.13.1748.
29. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10869-10874. 10.1073/pnas.191367098.
30. Lehmann B.D., Bauer J.a, Chen X., Sanders M.E., Chakravarthy a B., Shyr Y., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011, 121:2750-2767. 10.1172/JCI45014.
31. Chacón R.D., Costanzo M.V. Triple-negative breast cancer. Breast Cancer Res. 2010, 12(Suppl. 2):S3. 10.1186/bcr2574.
32. Hudis C.a, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011, 16(Suppl. 1):1-11. 10.1634/theoncologist.2011-S1-01.
33. Cheang M.C.U., Voduc D., Bajdik C., Leung S., McKinney S., Chia S.K., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 2008, 14:1368-1376. 10.1158/1078-0432.CCR-07-1658.
34. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8418-8423. 10.1073/pnas.0932692100.
35. de Ruijter T.C., Veeck J., de Hoon J.P.J., van Engeland M., Tjan-Heijnen V.C. Characteristics of triple-negative breast cancer. J. Cancer Res. Clin. Oncol. 2011, 137:183-192. 10.1007/s00432-010-0957-x.
36. Foulkes W.D., Stefansson I.M., Chappuis P.O., Bégin L.R., Goffin J.R., Wong N., et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl. Cancer Inst. 2003, 95:1482-1485. (http://www.ncbi.nlm.nih.gov/pubmed/14519755).
37. Lakhani S.R., Reis-Filho J.S., Fulford L., Penault-Llorca F., van der Vijver M., Parry S., et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 2005, 11:5175-5180. 10.1158/1078-0432.CCR-04-2424.
38. Gonzalez-Angulo A.M., Timms K.M., Liu S., Chen H., Litton J.K., Potter J., et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin. Cancer Res. 2011, 17:1082-1089. 10.1158/1078-0432.CCR-10-2560.
39. Turner N., Tutt A., Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat. Rev. Cancer 2004, 4:814-819. 10.1038/nrc1457.
40. Overgaard J., Yilmaz M., Guldberg P., Hansen L.L., Alsner J. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol. 2000, 39:327-333. (http://www.ncbi.nlm.nih.gov/pubmed/10987229).
41. D'Andrea A.D., Grompe M. The Fanconi anaemia/BRCA pathway. Nat. Rev. Cancer 2003, 3:23-34. 10.1038/nrc970.
42. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374. 10.1038/35077232.
43. Farmer H., McCabe N., Lord C.J., Tutt A.N.J., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921. 10.1038/nature03445.
44. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361:123-134. 10.1056/NEJMoa0900212.
45. Tutt A., Robson M., Garber J.E., Domchek S., Audeh M.W., Weitzel J.N., et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. ASCO, Meet. Abstr. 2009, 27:CRA501. (http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/27/18S/CRA501).
46. Tutt A., Robson M., Garber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244. 10.1016/S0140-6736(10)60892-6.
47. Gelmon K.A., Tischkowitz M., Mackay H., Swenerton K., Robidoux A., Tonkin K., et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011, 12:852-861. 10.1016/S1470-2045(11)70214-5.
48. O'Shaughnessy J., Osborne C., Pippen J.E., Yoffe M., Patt D., Rocha C., et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 2011, 364:205-214. 10.1056/NEJMoa1011418.
49. O'Shaughnessy J., Schwartzberg L., Danso M., Rugo H., Miller K., Yardley D. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). | 2011 ASCO Annual Meeting | Abstracts | Meeting Library, J. Clin. Oncol. 2011, (http://meetinglibrary.asco.org/content/78038-102).
50. Isakoff S.J., Overmoyer B., Tung N.M., Gelman R.S., Giranda V.L., Bernhard K.M., et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. ASCO, Meet. Abstr. 2010, 28:1019. (http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1019).
51. Dent R.A., Lindeman G.J., Clemons M., Wildiers H., Chan A., McCarthy N.J., et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2013, 15:R88. 10.1186/bcr3484.
52. Tan A., Gibbon D., Stein M., Moss R., Karantza V., Lin H., et al. Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide. J. Clin. Oncol. 2010, 28(15):3000. (http://meetinglibrary.asco.org/content/43189-74).
53. Gelmon K., Dent R., Mackey J.R., Laing K., McLeod D., Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann. Oncol. 2012, 23:2223-2234. 10.1093/annonc/mds067.
54. Bhattacharyya G.S., Basu S., Agarwal V., Malhotra H., Pareekh P.M., Babu K.G., et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative. Eur. J. Cancer 2009, (Suppl. 7):18-19. 10.1016/S1359-6349(09)72076-2.
55. Carey L.A., Rugo H.S., Marcom P.K., Mayer E.L., Esteva F.J., Ma C.X., et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J. Clin. Oncol. 2012, 30:2615-2623. 10.1200/JCO.2010.34.5579.
56. Alba E., Chacon J.I., Lluch A., Anton A., Estevez L., Cirauqui B., et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res. Treat. 2012, 136:487-493. 10.1007/s10549-012-2100-y.
57. Pal S.K., Childs B.H., Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res. Treat. 2011, 125:627-636. 10.1007/s10549-010-1293-1.
58. Frasci G., Comella P., Rinaldo M., Iodice G., Di Bonito M., D'Aiuto M., et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann. Oncol. 2009, 20:1185-1192. 10.1093/annonc/mdn748.
59. Liu M., Mo Q.-G., Wei C.-Y., Qin Q.-H., Huang Z., He J. Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis. Oncol. Lett. 2013, 5:983-991. 10.3892/ol.2012.1093.
60. Sikov W.M., Berry D.A., Perou C.M., Singh B., Cirrincione C.T., Tolaney S.M., et al. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603. Am. J. Clin. Oncol. 2014, (JCO.2014.57.0572-). 10.1200/JCO.2014.57.0572.
61. Fornier M., Fumoleau P. The paradox of triple negative breast cancer: novel approaches to treatment. Breast J. 2012, 18:41-51. 10.1111/j.1524-4741.2011.01175.x.
62. Thomas E.S., Gomez H.L., Li R.K., Chung H.-C., Fein L.E., Chan V.F., et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 2007, 25:5210-5217. 10.1200/JCO.2007.12.6557.
63. Bunnell C., Vahdat L., Schwartzberg L., Gralow J., Klimovsky J., Poulart V., et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin. Breast Cancer 2008, 8:234-241. 10.3816/CBC.2008.n.026.
64. Rugo H., Roche H., Thomas E., Blackwell K., Chung H., Lerzo G., et al. Ixabepilone plus capecitabine vs. capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies [abstract 3057]. Cancer Res. 2009, 69:225.
65. Linderholm B.K., Hellborg H., Johansson U., Elmberger G., Skoog L., Lehtiö J., et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann. Oncol. 2009, 20:1639-1646. 10.1093/annonc/mdp062.
66. Burstein H.J., Elias A.D., Rugo H.S., Cobleigh M.A., Wolff A.C., Eisenberg P.D., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2008, 26:1810-1816. 10.1200/JCO.2007.14.5375.
67. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004, 10:5367-5374. 10.1158/1078-0432.CCR-04-0220.
68. Finn R.S., Dering J., Ginther C., Wilson C.A., Glaspy P., Tchekmedyian N., et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res. Treat. 2007, 105:319-326. 10.1007/s10549-006-9463-x.
69. Ellard S.L., Clemons M., Gelmon K.A., Norris B., Kennecke H., Chia S., et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J. Clin. Oncol. 2009, 27:4536-4541. 10.1200/JCO.2008.21.3033.
70. O'Shaughnessy J., Dieras V., Glaspy J., Brufsky A., Miller K., Miles D., et al. Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC) [Astract 207]. Cancer Res. 2009, 69.
71. von Minckwitz G., Eidtmann H., Rezai M., Fasching P.A., Tesch H., Eggemann H., et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N. Engl. J. Med. 2012, 366:299-309. 10.1056/NEJMoa1111065.
72. Bear H.D., Tang G., Rastogi P., Geyer C.E., Robidoux A., Atkins J.N., et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N. Engl. J. Med. 2012, 366:310-320. 10.1056/NEJMoa1111097.
73. Crown J., O'Shaughnessy J., Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann. Oncol. 2012, 23(Suppl. 6):vi56-vi65. 10.1093/annonc/mds196.
74. Goozner M. Avastin hearing leads to more uncertainty over drug's future. J. Natl. Cancer Inst. 2011, 103:1148-1150. 10.1093/jnci/djr293.
75. Ranpura V., Hapani S., Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011, 305:487-494. 10.1001/jama.2011.51.
76. Baselga J., Gomez P., Awada A., Greil R., Braga S., Climent M., et al. The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1). Ann. Oncol. 2010, 21:viii96-viii121. 10.1093/annonc/mdq517.
77. O'Shaughnessy J., Weckstein D., Vukelja S., McIntyre K., Krekow L., Holmes F., et al. Randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer [Abstract 308]. Breast Cancer Res. Treat. 2007, 106.
78. Carey L., O'Shaughnessy J., Hoadley K., Khambata-Ford S., Horak C., Xu L., et al. Potential predictive markers of benefit from cetuximab in metastatic breast cancer: an analysis of two randomized phase 2 trials [Abstract 2014]. Cancer Res. 2009, 69.
79. Finn R.S., Bengala C., Ibrahim N., Roché H., Sparano J., Strauss L.C., et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin. Cancer Res. 2011, 17:6905-6913. 10.1158/1078-0432.CCR-11-0288.
80. Brower V. Search for new treatments intensifies for triple-negative breast cancer. J. Natl. Cancer Inst. 2009, 101:1536-1537. 10.1093/jnci/djp422.
81. Bergh J., Bondarenko I.M., Lichinitser M.R., Liljegren A., Greil R., Voytko N.L., et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J. Clin. Oncol. 2012, 30:921-929. 10.1200/JCO.2011.35.7376.
82. Crown J., Dieras V., Staroslawska E., Yardley D.A., Davidson N., Bachelot T.D., et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). ASCO Meet. Abstr. 2010, 28:LBA1011. (http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA1011).
83. Sun T., Aceto N., Meerbrey K.L., Kessler J.D., Zhou C., Migliaccio I., et al. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 2011, 144:703-718. 10.1016/j.cell.2011.02.003.
84. Meric-Bernstam F., Gonzalez-Angulo A.M. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 2009, 27:2278-2287. 10.1200/JCO.2008.20.0766.
85. Minami C.A., Chung D.U., Chang H.R. Management options in triple-negative breast cancer. Breast Cancer (Auckl.) 2011, 5:175-199. 10.4137/BCBCR.S6562.
86. Hennessy B.T., Gonzalez-Angulo A.-M., Stemke-Hale K., Gilcrease M.Z., Krishnamurthy S., Lee J.-S., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009, 69:4116-4124. 10.1158/0008-5472.CAN-08-3441.
87. Gonzalez-Angulo A., Green M., Murray J., Palla S., Koenig K., Brewster A., et al. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). J. Clin. Oncol. 2011, 29. (Abstr 1016, presented data-ASCO Annual Meeting 2011. http://meetinglibrary.asco.org/content/77698-102).
88. Wu Y., Sarkissyan M., Elshimali Y., Vadgama J.V. Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN. PLoS One 2013, 8:e78259. 10.1371/journal.pone.0078259.
89. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10314-10319. 10.1073/pnas.171076798.
90. Steelman L.S., Navolanic P.M., Sokolosky M.L., Taylor J.R., Lehmann B.D., Chappell W.H., et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 2008, 27:4086-4095. 10.1038/onc.2008.49.
91. Noh W.-C., Mondesire W.H., Peng J., Jian W., Zhang H., Dong J., et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin. Cancer Res. 2004, 10:1013-1023. (http://www.ncbi.nlm.nih.gov/pubmed/14871980).
92. Gucalp A., Traina T.A. Triple-negative breast cancer: role of the androgen receptor. Cancer J. 2010, 16. 62-5. http://dx.doi.org/10.1097/PPO.0b013e3181ce4ae1.
93. Doane A.S., Danso M., Lal P., Donaton M., Zhang L., Hudis C., et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006, 25:3994-4008. 10.1038/sj.onc.1209415.
94. Park S., Koo J., Park H.S., Kim J.-H., Choi S.-Y., Lee J.H., et al. Expression of androgen receptors in primary breast cancer. Ann. Oncol. 2010, 21:488-492. 10.1093/annonc/mdp510.
95. Gonzalez-Angulo A.M., Stemke-Hale K., Palla S.L., Carey M., Agarwal R., Meric-Berstam F., et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin. Cancer Res. 2009, 15:2472-2478. 10.1158/1078-0432.CCR-08-1763.
96. Traina T., Wolff A., Giri D., Feigin K., Patil S., Yuan J., et al. Androgen receptor inhibition for the treatment of AR+/ER-/PR- metastatic breast cancer [Abstract 251]. ASCO Breast Cancer Symp. 2009.
97. Brehm A., Miska E.A., McCance D.J., Reid J.L., Bannister A.J., Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998, 391:597-601. 10.1038/35404.
98. Uehara N., Kanematsu S., Miki H., Yoshizawa K., Tsubura A. Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells. Cancer Lett. 2012, 315:112-121. 10.1016/j.canlet.2011.07.032.
99. Sirois I., Groleau J., Pallet N., Brassard N., Hamelin K., Londono I., et al. Caspase activation regulates the extracellular export of autophagic vacuoles. Autophagy 2012, 8:927-937. 10.4161/auto.19768.
100. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306. 10.1038/nrc3245.
101. de la Cruz-Merino L., Barco-Sánchez A., Henao Carrasco F., Nogales Fernández E., Vallejo Benítez A., Brugal Molina J., et al. New insights into the role of the immune microenvironment in breast carcinoma. Clin. Dev. Immunol. 2013, 2013:785317. 10.1155/2013/785317.
102. Denkert C., Loibl S., Noske A., Roller M., Müller B.M., Komor M., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 2010, 28:105-113. 10.1200/JCO.2009.23.7370.
103. Denkert C., Loibl S., Salat C., Sinn B., Schem C., Endris V., et al. Abstract S1-06: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). Cancer Res. 2014, 73. (S1-06-S1-06). 10.1158/0008-5472.SABCS13-S1-06.
104. Adams S., Gray R.J., Demaria S., Goldstein L., Perez E.A., Shulman L.N., et al. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol. 2014, 10.1200/JCO.2013.55.0491.
105. Stagg J., Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther. Adv. Med. Oncol. 2013, 5:169-181. 10.1177/1758834012475152.
106. Bertucci F., Finetti P., Cervera N., Charafe-Jauffret E., Mamessier E., Adélaïde J., et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006, 66:4636-4644. 10.1158/0008-5472.CAN-06-0031.
107. Haakensen V.D., Lingjaerde O.C., Lüders T., Riis M., Prat A., Troester M.A., et al. Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. BMC Med. Genomics 2011, 4:77. 10.1186/1755-8794-4-77.
108. Arnedos M., Bihan C., Delaloge S., Andre F. Triple-negative breast cancer: are we making headway at least?. Ther. Adv. Med. Oncol. 2012, 4:195-210. 10.1177/1758834012444711.
109. O'Toole S.A., Beith J.M., Millar E.K.A., West R., McLean A., Cazet A., et al. Therapeutic targets in triple negative breast cancer. J. Clin. Pathol. 2013, 66:530-542. 10.1136/jclinpath-2012-201361.
110. Balko J.M., Giltnane J.M., Wang K., Schwarz L.J., Young C.D., Cook R.S., et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014, 4:232-245. 10.1158/2159-8290.CD-13-0286.
111. Janku F., McConkey D.J., Hong D.S., Kurzrock R. Autophagy as a target for anticancer therapy. Nat. Rev. Clin. Oncol. 2011, 8:528-539. 10.1038/nrclinonc.2011.71.
112. Saab R. Cellular senescence: many roads, one final destination. ScientificWorldJournal 2010, 10:727-741. 10.1100/tsw.2010.68.
113. Degenhardt K., Mathew R., Beaudoin B., Bray K., Anderson D., Chen G., et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006, 10:51-64. 10.1016/j.ccr.2006.06.001.
114. Watson J.a, Watson C.J., McCrohan A.-M., Woodfine K., Tosetto M., McDaid J., et al. Generation of an epigenetic signature by chronic hypoxia in prostate cells. Hum. Mol. Genet. 2009, 18:3594-3604. 10.1093/hmg/ddp307.
115. Longley D.B., Johnston P.G. Molecular mechanisms of drug resistance. J. Pathol. 2005, 205:275-292. 10.1002/path.1706.
116. Abdullah L.N., Chow E.K.-H. Mechanisms of chemoresistance in cancer stem cells. Clin. Transl. Med. 2013, 2:3. 10.1186/2001-1326-2-3.
117. Leonessa F., Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr. Relat. Cancer 2003, 10:43-73. (http://www.ncbi.nlm.nih.gov/pubmed/12653670).
118. Chow E.K.-H., Fan L., Chen X., Bishop J.M. Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells. Hepatology 2012, 56:1331-1341. 10.1002/hep.25776.
119. Shapiro A.B., Corder A.B., Ling V. P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur. J. Biochem. 1997, 250:115-121. (http://www.ncbi.nlm.nih.gov/pubmed/9431998).
120. Scharenberg C.W., Harkey M.A., Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002, 99:507-512. (http://www.ncbi.nlm.nih.gov/pubmed/11781231).
121. Tommasi S., Mangia A., Lacalamita R., Bellizzi A., Fedele V., Chiriatti A., et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int. J. Cancer 2007, 120:2078-2085. 10.1002/ijc.22557.
122. Paradiso A., Mangia A., Chiriatti A., Tommasi S., Zito A., Latorre A., et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann. Oncol. 2005, 16(Suppl. 4):iv14-iv19. 10.1093/annonc/mdi902.
123. Giaccone G., Pinedo H. Drug Resistance. Oncologist 1996, 1:82-87. (http://www.ncbi.nlm.nih.gov/pubmed/10387972).
124. Valkov N.I., Sullivan D.M. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Semin. Hematol. 1997, 34:48-62. (http://www.ncbi.nlm.nih.gov/pubmed/940896).
125. Fedier A., Schwarz V.A., Walt H., Carpini R.D., Haller U., Fink D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int. J. Cancer 2001, 93:571-576. (http://www.ncbi.nlm.nih.gov/pubmed/11477562).
126. Végran F., Boidot R., Oudin C., Riedinger J.-M., Bonnetain F., Lizard-Nacol S. Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clin. Cancer Res. 2006, 12:5794-5800. 10.1158/1078-0432.CCR-06-0725.
127. O'Connor P.M., Jackman J., Bae I., Myers T.G., Fan S., Mutoh M., et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997, 57:4285-4300. (http://www.ncbi.nlm.nih.gov/pubmed/9331090).
128. Aas T., Børresen A.L., Geisler S., Smith-Sørensen B., Johnsen H., Varhaug J.E., et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 1996, 2:811-814. (http://www.ncbi.nlm.nih.gov/pubmed/8673929).
129. Andersson J., Larsson L., Klaar S., Holmberg L., Nilsson J., Inganäs M., et al. Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Ann. Oncol. 2005, 16:743-748. 10.1093/annonc/mdi150.
130. Dumontet C., Sikic B.I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 1999, 17:1061-1070. (http://www.ncbi.nlm.nih.gov/pubmed/10071301).
131. Sládek N.E., Kollander R., Sreerama L., Kiang D.T. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherap. Cancer Chemother. Pharmacol. 2002, 49:309-321. 10.1007/s00280-001-0412-4.
132. DeGregorio M., Perez E. Molecular mechanisms of drug resistance. Cecil Textb. Med. 1996, 1056-1060.
133. Bedard P.L., Di Leo A., Piccart-Gebhart M.J. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat. Rev. Clin. Oncol. 2010, 7:22-36. 10.1038/nrclinonc.2009.186.
134. Yip N.C., Fombon I.S., Liu P., Brown S., Kannappan V., Armesilla A.L., et al. Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br. J. Cancer 2011, 104:1564-1574. 10.1038/bjc.2011.126.
135. Singel S.M., Cornelius C., Zaganjor E., Batten K., Sarode V.R., Buckley D.L., et al. KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. Neoplasia 2014, 16(247-56):256.e2. 10.1016/j.neo.2014.03.008.
136. Chekhun V.F., Zhylchuk V.E., Lukyanova N.Y., Vorontsova A.L., Kudryavets Y.I. Expression of drug resistance proteins in triple-receptor-negative tumors as the basis of individualized therapy of the breast cancer patients. Exp. Oncol. 2009, 31:123-124. (http://www.ncbi.nlm.nih.gov/pubmed/19550405).
137. Zhou F., Yan M., Guo G., Wang F., Qiu H., Zheng F., et al. Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med. Oncol. 2011, 28:1302-1307. 10.1007/s12032-010-9630-0.
138. Nolen B.M., Marks J.R., Ta'san S., Rand A., Luong T.M., Wang Y., et al. Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res. 2008, 10:R45. 10.1186/bcr2096.
139. Bauer J.A., Chakravarthy A.B., Rosenbluth J.M., Mi D., Seeley E.H., De Matos Granja-Ingram N., et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin. Cancer Res. 2010, 16:681-690. 10.1158/1078-0432.CCR-09-1091.
140. Ivanov O., Chen F., Wiley E.L., Keswani A., Diaz L.K., Memmel H.C., et al. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res. Treat. 2008, 111:411-417. 10.1007/s10549-007-9796-0.
141. Giricz O., Calvo V., Pero S.C., Krag D.N., Sparano J.A., Kenny P.A. GRB7 is required for triple-negative breast cancer cell invasion and survival. Breast Cancer Res. Treat. 2012, 133:607-615. 10.1007/s10549-011-1822-6.
142. Anders C.K., Winer E.P., Ford J.M., Dent R., Silver D.P., Sledge G.W., et al. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin. Cancer Res. 2010, 16:4702-4710. 10.1158/1078-0432.CCR-10-0939.
143. Alli E., Sharma V.B., Sunderesakumar P., Ford J.M. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res. 2009, 69:3589-3596. 10.1158/0008-5472.CAN-08-4016.
144. Graham T.R., Yacoub R., Taliaferro-Smith L., Osunkoya A.O., Odero-Marah V.A., Liu T., et al. Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Res. Treat. 2010, 123:139-147. 10.1007/s10549-009-0623-7.
145. Liedtke C., Mazouni C., Hess K.R., André F., Tordai A., Mejia J.A., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008, 26:1275-1281. 10.1200/JCO.2007.14.4147.
146. André F., Zielinski C.C. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann. Oncol. 2012, 23(Suppl. 6):vi46-vi51. 10.1093/annonc/mds195.
147. Dalerba P., Cho R.W., Clarke M.F. Cancer stem cells: models and concepts. Annu. Rev. Med. 2007, 58:267-284. 10.1146/annurev.med.58.062105.204854.
148. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648. 10.1038/367645a0.
149. Mani S.A., Guo W., Liao M.-J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027.
150. Bhola N., Balko J. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Investig. 2013, 123. 10.1172/JCI65416DS1.
151. Samanta D., Gilkes D.M., Chaturvedi P., Xiang L., Semenza G.L. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc. Natl. Acad. Sci. U. S. A. 2014, 5429-5438. 10.1073/pnas.1421438111.
152. Vera-Ramirez L., Sanchez-Rovira P., Ramirez-Tortosa M.C., Ramirez-Tortosa C.L., Granados-Principal S., Lorente J.A., et al. Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies. Crit. Rev. Oncol. Hematol. 2011, 80:347-368. 10.1016/j.critrevonc.2011.01.004.
153. Koo J.S., Jung W. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer. Pathobiology 2010, 77:289-300. 10.1159/000320936.
154. Basu S., Chen W., Tchou J., Mavi A., Cermik T., Czerniecki B., et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for d. Cancer 2008, 112:995-1000. 10.1002/cncr.23226.
155. Lee S.-J., Kim H.-P., Jin Y., Choi A.M.K., Ryter S.W. Beclin 1 deficiency is associated with increased hypoxia-induced angiogenesis. Autophagy 2011, 7:829-839. (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3149693&tool=pmcentrez&rendertype=abstract).
156. Cosse J.-P., Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anti Cancer Agents Med. Chem. 2008, 8:790-797. (http://www.ncbi.nlm.nih.gov/pubmed/18855580).
157. Milane L., Duan Z., Amiji M. Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int. 2011, 11:3. 10.1186/1475-2867-11-3.
158. Prencipe M., McGoldrick A., Perry A.S., O'Grady A., Phelan S., McGrogan B., et al. MAD2 downregulation in hypoxia is independent of promoter hypermethylation. Cell Cycle 2010, 9:2856-2865. (http://www.ncbi.nlm.nih.gov/pubmed/20676051).
159. Groheux D., Hindié E., Giacchetti S., Delord M., Hamy A.-S., de Roquancourt A., et al. Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J. Nucl. Med. 2012, 53:249-254. 10.2967/jnumed.111.094045.
160. Neumeister V.M., Sullivan C.a, Lindner R., Lezon-Geyda K., Li J., Zavada J., et al. Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer. Breast Cancer Res. Treat. 2012, 136:67-75. 10.1007/s10549-012-2232-0.
161. Tan E.Y., Yan M., Campo L., Han C., Takano E., Turley H., et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br. J. Cancer 2009, 100:405-411. 10.1038/sj.bjc.6604844.
162. Bernardi R., Gianni L. Hallmarks of triple negative breast cancer emerging at last?. Cell Res. 2014, 24:904-905. 10.1038/cr.2014.61.
163. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., et al. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642. 10.1038/436642a.
164. Chakrabarti J., Turley H., Campo L., Han C., Harris A.L., Gatter K.C., et al. The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers. Br. J. Cancer 2004, 91:954-958. 10.1038/sj.bjc.6602059.
165. Pare R., Yang T., Shin J.-S., Lee C.S. The significance of the senescence pathway in breast cancer progression. J. Clin. Pathol. 2013, 66:491-495. 10.1136/jclinpath-2012-201081.
166. Tchou J., Sonnad S.S., Bergey M.R., Basu S., Tomaszewski J., Alavi A., et al. Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol. Imaging Biol. 2010, 12:657-662. 10.1007/s11307-009-0294-0.
167. Keam B., Im S.-A., Koh Y., Han S.-W., Oh D.-Y., Cho N., et al. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer 2011, 11:452. 10.1186/1471-2407-11-452.
168. Ueda S., Tsuda H., Asakawa H., Shigekawa T., Fukatsu K., Kondo N., et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn. J. Clin. Oncol. 2008, 38:250-258. 10.1093/jjco/hyn019.
169. Kim B.S., Sung S.H. Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann. Nucl. Med. 2012, 26:175-183. 10.1007/s12149-011-0556-1.
170. Dogan B.E., Turnbull L.W. Imaging of triple-negative breast cancer. Ann. Oncol. 2012, 23(Suppl. 6):vi23-vi29. 10.1093/annonc/mds191.
171. Hammond E.M., Giaccia A.J. The role of p53 in hypoxia-induced apoptosis. Biochem. Biophys. Res. Commun. 2005, 331:718-725. 10.1016/j.bbrc.2005.03.154.
172. Welford S.M., Giaccia A.J. Hypoxia and senescence: the impact of oxygenation on tumor suppression. Mol. Cancer Res. 2011, 9:538-544. 10.1158/1541-7786.MCR-11-0065.
173. Cao M.D., Sitter B., Bathen T.F., Bofin A., Lønning P.E., Lundgren S., et al. Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR Biomed. 2012, 25:369-378. 10.1002/nbm.1762.
174. Witkiewicz A.K., Whitaker-Menezes D., Dasgupta A., Philp N.J., Lin Z., Gandara R., et al. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle 2012, 11:1108-1117. 10.4161/cc.11.6.19530.
175. Ksiazek K., Mikula-Pietrasik J., Korybalska K., Dworacki G., Jörres A., Witowski J. Senescent peritoneal mesothelial cells promote ovarian cancer cell adhesion: the role of oxidative stress-induced fibronectin. Am. J. Pathol. 2009, 174:1230-1240. 10.2353/ajpath.2009.080613.
176. Fodil-Bourahla I., Drubaix I., Robert L., Labat-Robert J. Effect of in vitro aging on the modulation of protein and fibronectin biosynthesis by the elastin-laminin receptor in human skin fibroblasts. Gerontology 1999, 45:23-30. (http://www.ncbi.nlm.nih.gov/pubmed/9852377).
177. Grillari J., Hohenwarter O., Grabherr R.M., Katinger H. Subtractive hybridization of mRNA from early passage and senescent endothelial cells. Exp. Gerontol. 2000, 35:187-197. (http://www.ncbi.nlm.nih.gov/pubmed/10767578).
178. Porter M.B., Pereira-Smith O.M., Smith J.R. Novel monoclonal antibodies identify antigenic determinants unique to cellular senescence. J. Cell. Physiol. 1990, 142:425-433. 10.1002/jcp.1041420228.
179. Schulz D.M., Böllner C., Thomas G., Atkinson M., Esposito I., Höfler H., et al. Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J. Proteome Res. 2009, 8:3430-3438. 10.1021/pr900071h.
180. Saab R. Senescence and pre-malignancy: how do tumors progress?. Semin. Cancer Biol. 2011, 21:385-391. 10.1016/j.semcancer.2011.09.013.
181. Plath T., Detjen K., Welzel M., von Marschall Z., Murphy D., Schirner M., et al. A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor. J. Cell Biol. 2000, 150:1467-1478. (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2150704&tool=pmcentrez&rendertype=abstract).
182. Cho S.O., Kim K.H., Yoon J.-H., Kim H. Signaling for integrin alpha5/beta1 expression in Helicobacter pylori-infected gastric epithelial AGS cells. Ann. N. Y. Acad. Sci. 2006, 1090:298-304. 10.1196/annals.1378.032.
183. Krtolica A., Campisi J. Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int. J. Biochem. Cell Biol. 2002, 34:1401-1414. (http://www.ncbi.nlm.nih.gov/pubmed/12200035).
184. Yang G., Rosen D.G., Zhang Z., Bast R.C., Mills G.B., Colacino J.A., et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:16472-16477. 10.1073/pnas.0605752103.
185. Nishida K., Yamaguchi O., Otsu K. Crosstalk between autophagy and apoptosis in heart disease. Circ. Res. 2008, 103:343-351. 10.1161/CIRCRESAHA.108.175448.
186. Yang Y.-P., Liang Z.-Q., Gu Z.-L., Qin Z.-H. Molecular mechanism and regulation of autophagy. Acta Pharmacol. Sin. 2005, 26:1421-1434. 10.1111/j.1745-7254.2005.00235.x.
187. Kunz J.B., Schwarz H., Mayer A. Determination of four sequential stages during microautophagy in vitro. J. Biol. Chem. 2004, 279:9987-9996. 10.1074/jbc.M307905200.
188. Dice J.F. Chaperone-mediated autophagy. Autophagy 2007, 3:295-299. (http://www.ncbi.nlm.nih.gov/pubmed/17404494).
189. Levine B., Yuan J. Autophagy in cell death: an innocent convict?. J. Clin. Invest. 2005, 115:2679-2688. 10.1172/JCI26390.
190. Thorburn A. Apoptosis and autophagy: regulatory connections between two supposedly different processes. Apoptosis 2008, 13:1-9. 10.1007/s10495-007-0154-9.
191. Hoare M., Young A.R.J., Narita M. Autophagy in cancer: having your cake and eating it. Semin. Cancer Biol. 2011, 21:397-404. 10.1016/j.semcancer.2011.09.004.
192. Martinet W., Agostinis P., Vanhoecke B., Dewaele M., De Meyer G.R.Y. Autophagy in disease: a double-edged sword with therapeutic potential. Clin. Sci. (Lond.) 2009, 116:697-712. 10.1042/CS20080508.
193. Swampillai A.L., Salomoni P., Short S.C. The role of autophagy in clinical practice. Clin. Oncol. (R. Coll. Radiol.) 2012, 24:387-395. 10.1016/j.clon.2011.09.010.
194. Rikiishi H. Novel Insights into the Interplay between Apoptosis and Autophagy. Int. J. Cell Biol. 2012, 2012:317645. 10.1155/2012/317645.
195. Notte A., Leclere L., Michiels C. Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochem. Pharmacol. 2011, 82:427-434. 10.1016/j.bcp.2011.06.015.
196. Mathew R., Karantza-Wadsworth V., White E. Role of autophagy in cancer. Nat. Rev. Cancer 2007, 7:961-967. 10.1038/nrc2254.
197. Lorin S., Hamaï A., Mehrpour M., Codogno P. Autophagy regulation and its role in cancer. Semin. Cancer Biol. 2013, 23:361-379. 10.1016/j.semcancer.2013.06.007.
198. Eng C.H., Abraham R.T. The autophagy conundrum in cancer: influence of tumorigenic metabolic reprogramming. Oncogene 2011, 30:4687-4696. 10.1038/onc.2011.220.
199. Essick E.E., Sam F. Oxidative stress and autophagy in cardiac disease, neurological disorders, aging and cancer. Oxidative Med. Cell. Longev. 2010, 3:168-177. 10.4161/oxim.3.3.12106.
200. Martinez-Outschoorn U.E., Pavlides S., Howell A., Pestell R.G., Tanowitz H.B., Sotgia F., et al. Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. Int. J. Biochem. Cell Biol. 2011, 43:1045-1051. 10.1016/j.biocel.2011.01.023.
201. Xi G., Hu X., Wu B., Jiang H., Young C.Y.F., Pang Y., et al. Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells. Cancer Lett. 2011, 307:141-148. 10.1016/j.canlet.2011.03.026.
202. Notte A., Ninane N., Arnould T., Michiels C. Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation. Cell Death Dis. 2013, 4:e638. 10.1038/cddis.2013.167.
203. Mathew R., White E. Autophagy, stress, and cancer metabolism: what doesn't kill you makes you stronger. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:389-396. 10.1101/sqb.2012.76.011015.
204. Ávalos Y., Canales J., Bravo-Sagua R., Criollo A., Lavandero S., Quest A.F.G. Tumor suppression and promotion by autophagy. Biomed. Res. Int. 2014, 2014:603980. 10.1155/2014/603980.
205. Zhang H., Bosch-Marce M., Shimoda L.A., Tan Y.S., Baek J.H., Wesley J.B., et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem. 2008, 283:10892-10903. 10.1074/jbc.M800102200.
206. Bellot G., Garcia-Medina R., Gounon P., Chiche J., Roux D., Pouysségur J., et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol. Cell. Biol. 2009, 29:2570-2581. 10.1128/MCB. 00166-09.
207. Semenza G.L. Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning. Biochim. Biophys. Acta 2011, 1813:1263-1268. 10.1016/j.bbamcr.2010.08.006.
208. Choi J., Kim D.H., Jung W.H., Koo J.S. Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype. Breast Cancer Res. 2013, 15:R78. 10.1186/bcr3472.
209. Zhao H., Yang M., Zhao J., Wang J., Zhang Y., Zhang Q. High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer. Med. Oncol. 2013, 30:475. 10.1007/s12032-013-0475-1.
210. Singha P.K., Pandeswara S., Venkatachalam M.A., Saikumar P. Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death. Cell Death Dis. 2013, 4:e457. 10.1038/cddis.2012.192.
211. Thomas S., Sharma N., Golden E.B., Cho H., Agarwal P., Gaffney K.J., et al. Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer Lett. 2012, 325:63-71. 10.1016/j.canlet.2012.05.030.
212. Pike L.R.G., Singleton D.C., Buffa F., Abramczyk O., Phadwal K., Li J.-L., et al. Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival. Biochem. J. 2013, 449:389-400. 10.1042/BJ20120972.
213. Salem A.F., Howell A., Sartini M., Sotgia F., Lisanti M.P. Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1α, autophagy and ketone body production. Cell Cycle 2012, 11:4167-4173. 10.4161/cc.22316.
214. Sotgia F., Martinez-Outschoorn U.E., Pavlides S., Howell A., Pestell R.G., Lisanti M.P. Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res. 2011, 13:213. 10.1186/bcr2892.
215. Witkiewicz A.K., Kline J., Queenan M., Brody J.R., Tsirigos A., Bilal E., et al. Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle 2011, 10:1794-1809. (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3142463&tool=pmcentrez&rendertype=abstract).
216. Azad M.B., Chen Y., Henson E.S., Cizeau J., McMillan-Ward E., Israels S.J., et al. Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy 2008, 4:195-204. (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3164855&tool=pmcentrez&rendertype=abstract).
217. Tan E.Y., Campo L., Han C., Turley H., Pezzella F., Gatter K.C., et al. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clin. Cancer Res. 2007, 13:467-474. 10.1158/1078-0432.CCR-06-1466.
218. Dong X.L., Xu P.F., Miao C., Fu Z.Y., Li Q.P., Tang P.Y., et al. Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1. Biomed. Pharmacother. 2012, 66:70-75. 10.1016/j.biopha.2011.11.016.
219. Selvendiran K., Bratasz A., Kuppusamy M.L., Tazi M.F., Rivera B.K., Kuppusamy P. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int. J. Cancer 2009, 125:2198-2204. 10.1002/ijc.24601.
220. Sullivan R., Graham C.H. Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol. Cancer Ther. 2009, 8:1702-1713. 10.1158/1535-7163.MCT-08-1090.
221. Su W., Huang L., Ao Q., Zhang Q., Tian X., Fang Y., et al. Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1α. Cancer Lett. 2011, 305:94-99. 10.1016/j.canlet.2011.02.031.
222. Flamant L., Notte A., Ninane N., Raes M., Michiels C. Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol. Cancer 2010, 9:191. 10.1186/1476-4598-9-191.
223. Fitzgerald L.D., Bailey C.K., Brandt S.J., Thompson M.E. BRCA1 accumulates in the nucleus in response to hypoxia and TRAIL and enhances TRAIL-induced apoptosis in breast cancer cells. FEBS J. 2007, 274:5137-5146. 10.1111/j.1742-4658.2007.06033.x.
224. Plathow C., Weber W.A. Tumor cell metabolism imaging. J. Nucl. Med. 2008, 49(Suppl. 2):43S-63S. 10.2967/jnumed.107.045930.
225. Hirschhaeuser F., Sattler U.G.A., Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011, 71:6921-6925. 10.1158/0008-5472.CAN-11-1457.
226. Woo O.F., Mueller P.D., Olson K.R., Anderson I.B., Kim S.Y. Shorter duration of oral N-acetylcysteine therapy for acute acetaminophen overdose. Ann. Emerg. Med. 2000, 35:363-368. (http://www.ncbi.nlm.nih.gov/pubmed/10736123).
227. Bird S., Mazzola J., Brush D., Boyer E., Aaron C. A prospective evaluation of abbreviated oral N-acetylcysteine (NAC) therapy for acetaminophen poisoning. Acad. Emerg. Med. 2003, 10:521.
228. De Flora S., Izzotti A., D'Agostini F., Balansky R.M. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis 2001, 22:999-1013. (http://www.ncbi.nlm.nih.gov/pubmed/11408342).
229. Moradi M., Mojtahedzadeh M., Mandegari A., Soltan-Sharifi M.S., Najafi A., Khajavi M.R., et al. The role of glutathione-S-transferase polymorphisms on clinical outcome of ALI/ARDS patient treated with N-acetylcysteine. Respir. Med. 2009, 103:434-441. 10.1016/j.rmed.2008.09.013.
230. D'Agostini F., Bagnasco M., Giunciuglio D., Albini A., De Flora S. Inhibition by oral N-acetylcysteine of doxorubicin-induced clastogenicity and alopecia, and prevention of primary tumors and lung micrometastases in mice. Int. J. Oncol. 1998, 13:217-224. (http://www.ncbi.nlm.nih.gov/pubmed/9664114).
231. Havre P.A., O'Reilly S., McCormick J.J., Brash D.E. Transformed and tumor-derived human cells exhibit preferential sensitivity to the thiol antioxidants, N-acetyl cysteine and penicillamine. Cancer Res. 2002, 62:1443-1449. (http://www.ncbi.nlm.nih.gov/pubmed/11888918).
232. Gao P., Zhang H., Dinavahi R., Li F., Xiang Y., Raman V., et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007, 12:230-238. 10.1016/j.ccr.2007.08.004.
233. Albini A., Morini M., D'Agostini F., Ferrari N., Campelli F., Arena G., et al. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res. 2001, 61:8171-8178. (http://www.ncbi.nlm.nih.gov/pubmed/11719447).
234. Menon S.G., Coleman M.C., Walsh S.A., Spitz D.R., Goswami P.C. Differential susceptibility of nonmalignant human breast epithelial cells and breast cancer cells to thiol antioxidant-induced G(1)-delay. Antioxid. Redox Signal. 2005, 7:711-718. 10.1089/ars.2005.7.711.
235. Agarwal A., Muñoz-Nájar U., Klueh U., Shih S.-C., Claffey K.P. N-acetyl-cysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer. Am. J. Pathol. 2004, 164:1683-1696. 10.1016/S0002-9440(10)63727-3.
236. Whitaker-Menezes D., Martinez-Outschoorn U.E., Lin Z., Ertel A., Flomenberg N., Witkiewicz A.K., et al. Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011, 10:1772-1783. (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3142461&tool=pmcentrez&rendertype=abstract).
237. Martinez-Outschoorn U.E., Balliet R., Lin Z., Whitaker-Menezes D., Birbe R.C., Bombonati A., et al. BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. Cell Cycle 2012, 11:4402-4413. 10.4161/cc.22776.
238. U.E. Martinez-Outschoorn, R. Balliet, Z. Lin, D. Whitaker-Menezes, R.C. Birbe, A. Bombonati, et al., BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies, Cell Cycle 11 (2012) 4402-4413, http://dx.doi.org/10.4161/cc.22776.